COVID-19 Impact on Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size, Status and Forecast 2020-2026

July 2020 | 126 pages | ID: C9ABDEA88C0DEN
QYResearch

Abstracts

This report focuses on the global Paclitaxel and Its Analogue in Anticarcinoma Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Paclitaxel and Its Analogue in Anticarcinoma Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Bristol-Myers Squibb
• Celgene Corporation
• Hospira
• Biological E.
• Taj Accura
• Khandelwal Laboratories
• Luye Pharma
• Beijing Youcare
• Beijing Union
• Haiyao
• Chuntch
• Hengrui Medicine
• Sanofi
• Qilu Pharma
• Shenzhen Main Luck Pharma
• Jiangsu Aosaikang Pharma
• CSPC Pharmaceutical
• Aosaikang Pharm

Market segment by Type, the product can be split into

• Paclitaxel
• Docetaxel
• Liposome Paclitaxel
• Protein-bound Paclitaxel

Market segment by Application, split into

• Ovarian Cancer
• Breast Cancer
• Cervical Cancer
• Pancreatic Cancer
• Non-small Cell Lung Cancer
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Paclitaxel and Its Analogue in Anticarcinoma Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Paclitaxel and Its Analogue in Anticarcinoma Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Paclitaxel and Its Analogue in Anticarcinoma Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Paclitaxel
  1.4.3 Docetaxel
  1.4.4 Liposome Paclitaxel
  1.4.5 Protein-bound Paclitaxel
1.5 Market by Application
  1.5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Ovarian Cancer
  1.5.3 Breast Cancer
  1.5.4 Cervical Cancer
  1.5.5 Pancreatic Cancer
  1.5.6 Non-small Cell Lung Cancer
  1.5.7 Other
1.6 Coronavirus Disease 2019 (Covid-19): Paclitaxel and Its Analogue in Anticarcinoma Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Paclitaxel and Its Analogue in Anticarcinoma Drugs Industry
    1.6.1.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Paclitaxel and Its Analogue in Anticarcinoma Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Paclitaxel and Its Analogue in Anticarcinoma Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Perspective (2015-2026)
2.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Growth Trends by Regions
  2.2.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Paclitaxel and Its Analogue in Anticarcinoma Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Paclitaxel and Its Analogue in Anticarcinoma Drugs Players by Market Size
  3.1.1 Global Top Paclitaxel and Its Analogue in Anticarcinoma Drugs Players by Revenue (2015-2020)
  3.1.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Concentration Ratio
  3.2.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue in 2019
3.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players Head office and Area Served
3.4 Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Product Solution and Service
3.5 Date of Enter into Paclitaxel and Its Analogue in Anticarcinoma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Forecasted Market Size by Type (2021-2026)

5 PACLITAXEL AND ITS ANALOGUE IN ANTICARCINOMA DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)
5.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
6.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in North America (2019-2020)
6.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
6.4 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
7.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Europe (2019-2020)
7.3 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
7.4 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
8.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in China (2019-2020)
8.3 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
8.4 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
9.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Japan (2019-2020)
9.3 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
9.4 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
10.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
11.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in India (2019-2020)
11.3 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
11.4 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2015-2020)
12.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Bristol-Myers Squibb
  13.1.1 Bristol-Myers Squibb Company Details
  13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  13.1.3 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.1.4 Bristol-Myers Squibb Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020))
  13.1.5 Bristol-Myers Squibb Recent Development
13.2 Celgene Corporation
  13.2.1 Celgene Corporation Company Details
  13.2.2 Celgene Corporation Business Overview and Its Total Revenue
  13.2.3 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.2.4 Celgene Corporation Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.2.5 Celgene Corporation Recent Development
13.3 Hospira
  13.3.1 Hospira Company Details
  13.3.2 Hospira Business Overview and Its Total Revenue
  13.3.3 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.3.4 Hospira Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.3.5 Hospira Recent Development
13.4 Biological E.
  13.4.1 Biological E. Company Details
  13.4.2 Biological E. Business Overview and Its Total Revenue
  13.4.3 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.4.4 Biological E. Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.4.5 Biological E. Recent Development
13.5 Taj Accura
  13.5.1 Taj Accura Company Details
  13.5.2 Taj Accura Business Overview and Its Total Revenue
  13.5.3 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.5.4 Taj Accura Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.5.5 Taj Accura Recent Development
13.6 Khandelwal Laboratories
  13.6.1 Khandelwal Laboratories Company Details
  13.6.2 Khandelwal Laboratories Business Overview and Its Total Revenue
  13.6.3 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.6.4 Khandelwal Laboratories Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.6.5 Khandelwal Laboratories Recent Development
13.7 Luye Pharma
  13.7.1 Luye Pharma Company Details
  13.7.2 Luye Pharma Business Overview and Its Total Revenue
  13.7.3 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.7.4 Luye Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.7.5 Luye Pharma Recent Development
13.8 Beijing Youcare
  13.8.1 Beijing Youcare Company Details
  13.8.2 Beijing Youcare Business Overview and Its Total Revenue
  13.8.3 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.8.4 Beijing Youcare Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.8.5 Beijing Youcare Recent Development
13.9 Beijing Union
  13.9.1 Beijing Union Company Details
  13.9.2 Beijing Union Business Overview and Its Total Revenue
  13.9.3 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.9.4 Beijing Union Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.9.5 Beijing Union Recent Development
13.10 Haiyao
  13.10.1 Haiyao Company Details
  13.10.2 Haiyao Business Overview and Its Total Revenue
  13.10.3 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  13.10.4 Haiyao Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  13.10.5 Haiyao Recent Development
13.11 Chuntch
  10.11.1 Chuntch Company Details
  10.11.2 Chuntch Business Overview and Its Total Revenue
  10.11.3 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.11.4 Chuntch Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.11.5 Chuntch Recent Development
13.12 Hengrui Medicine
  10.12.1 Hengrui Medicine Company Details
  10.12.2 Hengrui Medicine Business Overview and Its Total Revenue
  10.12.3 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.12.4 Hengrui Medicine Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.12.5 Hengrui Medicine Recent Development
13.13 Sanofi
  10.13.1 Sanofi Company Details
  10.13.2 Sanofi Business Overview and Its Total Revenue
  10.13.3 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.13.4 Sanofi Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.13.5 Sanofi Recent Development
13.14 Qilu Pharma
  10.14.1 Qilu Pharma Company Details
  10.14.2 Qilu Pharma Business Overview and Its Total Revenue
  10.14.3 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.14.4 Qilu Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.14.5 Qilu Pharma Recent Development
13.15 Shenzhen Main Luck Pharma
  10.15.1 Shenzhen Main Luck Pharma Company Details
  10.15.2 Shenzhen Main Luck Pharma Business Overview and Its Total Revenue
  10.15.3 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.15.4 Shenzhen Main Luck Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.15.5 Shenzhen Main Luck Pharma Recent Development
13.16 Jiangsu Aosaikang Pharma
  10.16.1 Jiangsu Aosaikang Pharma Company Details
  10.16.2 Jiangsu Aosaikang Pharma Business Overview and Its Total Revenue
  10.16.3 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.16.4 Jiangsu Aosaikang Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.16.5 Jiangsu Aosaikang Pharma Recent Development
13.17 CSPC Pharmaceutical
  10.17.1 CSPC Pharmaceutical Company Details
  10.17.2 CSPC Pharmaceutical Business Overview and Its Total Revenue
  10.17.3 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.17.4 CSPC Pharmaceutical Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.17.5 CSPC Pharmaceutical Recent Development
13.18 Aosaikang Pharm
  10.18.1 Aosaikang Pharm Company Details
  10.18.2 Aosaikang Pharm Business Overview and Its Total Revenue
  10.18.3 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
  10.18.4 Aosaikang Pharm Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
  10.18.5 Aosaikang Pharm Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue
Table 3. Ranking of Global Top Paclitaxel and Its Analogue in Anticarcinoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Paclitaxel
Table 6. Key Players of Docetaxel
Table 7. Key Players of Liposome Paclitaxel
Table 8. Key Players of Protein-bound Paclitaxel
Table 9. COVID-19 Impact Global Market: (Four Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Paclitaxel and Its Analogue in Anticarcinoma Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Paclitaxel and Its Analogue in Anticarcinoma Drugs Players to Combat Covid-19 Impact
Table 14. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Regions (2015-2020)
Table 18. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Growth Strategy
Table 24. Main Points Interviewed from Key Paclitaxel and Its Analogue in Anticarcinoma Drugs Players
Table 25. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Players (2015-2020) (Million US$)
Table 26. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Players (2015-2020)
Table 27. Global Top Paclitaxel and Its Analogue in Anticarcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs as of 2019)
Table 28. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Product Solution and Service
Table 31. Date of Enter into Paclitaxel and Its Analogue in Anticarcinoma Drugs Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 34. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Share by Type (2015-2020)
Table 35. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Type (2021-2026)
Table 36. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Share by Application (2015-2020)
Table 37. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Share by Application (2021-2026)
Table 39. North America Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 41. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 43. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 45. Europe Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 47. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 49. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 51. China Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 52. China Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 53. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 55. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 57. Japan Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 59. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 61. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 65. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 67. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 69. India Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 70. India Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 71. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 73. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share (2019-2020)
Table 77. Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type (2015-2020)
Table 79. Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2015-2020)
Table 81. Bristol-Myers Squibb Company Details
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Product
Table 84. Bristol-Myers Squibb Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 85. Bristol-Myers Squibb Recent Development
Table 86. Celgene Corporation Company Details
Table 87. Celgene Corporation Business Overview
Table 88. Celgene Corporation Product
Table 89. Celgene Corporation Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 90. Celgene Corporation Recent Development
Table 91. Hospira Company Details
Table 92. Hospira Business Overview
Table 93. Hospira Product
Table 94. Hospira Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 95. Hospira Recent Development
Table 96. Biological E. Company Details
Table 97. Biological E. Business Overview
Table 98. Biological E. Product
Table 99. Biological E. Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 100. Biological E. Recent Development
Table 101. Taj Accura Company Details
Table 102. Taj Accura Business Overview
Table 103. Taj Accura Product
Table 104. Taj Accura Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 105. Taj Accura Recent Development
Table 106. Khandelwal Laboratories Company Details
Table 107. Khandelwal Laboratories Business Overview
Table 108. Khandelwal Laboratories Product
Table 109. Khandelwal Laboratories Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 110. Khandelwal Laboratories Recent Development
Table 111. Luye Pharma Company Details
Table 112. Luye Pharma Business Overview
Table 113. Luye Pharma Product
Table 114. Luye Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 115. Luye Pharma Recent Development
Table 116. Beijing Youcare Business Overview
Table 117. Beijing Youcare Product
Table 118. Beijing Youcare Company Details
Table 119. Beijing Youcare Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 120. Beijing Youcare Recent Development
Table 121. Beijing Union Company Details
Table 122. Beijing Union Business Overview
Table 123. Beijing Union Product
Table 124. Beijing Union Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 125. Beijing Union Recent Development
Table 126. Haiyao Company Details
Table 127. Haiyao Business Overview
Table 128. Haiyao Product
Table 129. Haiyao Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 130. Haiyao Recent Development
Table 131. Chuntch Company Details
Table 132. Chuntch Business Overview
Table 133. Chuntch Product
Table 134. Chuntch Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 135. Chuntch Recent Development
Table 136. Hengrui Medicine Company Details
Table 137. Hengrui Medicine Business Overview
Table 138. Hengrui Medicine Product
Table 139. Hengrui Medicine Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 140. Hengrui Medicine Recent Development
Table 141. Sanofi Company Details
Table 142. Sanofi Business Overview
Table 143. Sanofi Product
Table 144. Sanofi Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 145. Sanofi Recent Development
Table 146. Qilu Pharma Company Details
Table 147. Qilu Pharma Business Overview
Table 148. Qilu Pharma Product
Table 149. Qilu Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 150. Qilu Pharma Recent Development
Table 151. Shenzhen Main Luck Pharma Company Details
Table 152. Shenzhen Main Luck Pharma Business Overview
Table 153. Shenzhen Main Luck Pharma Product
Table 154. Shenzhen Main Luck Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 155. Shenzhen Main Luck Pharma Recent Development
Table 156. Jiangsu Aosaikang Pharma Company Details
Table 157. Jiangsu Aosaikang Pharma Business Overview
Table 158. Jiangsu Aosaikang Pharma Product
Table 159. Jiangsu Aosaikang Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 160. Jiangsu Aosaikang Pharma Recent Development
Table 161. CSPC Pharmaceutical Company Details
Table 162. CSPC Pharmaceutical Business Overview
Table 163. CSPC Pharmaceutical Product
Table 164. CSPC Pharmaceutical Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 165. CSPC Pharmaceutical Recent Development
Table 166. Aosaikang Pharm Company Details
Table 167. Aosaikang Pharm Business Overview
Table 168. Aosaikang Pharm Product
Table 169. Aosaikang Pharm Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020) (Million US$)
Table 170. Aosaikang Pharm Recent Development
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Type: 2020 VS 2026
Figure 2. Paclitaxel Features
Figure 3. Docetaxel Features
Figure 4. Liposome Paclitaxel Features
Figure 5. Protein-bound Paclitaxel Features
Figure 6. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application: 2020 VS 2026
Figure 7. Ovarian Cancer Case Studies
Figure 8. Breast Cancer Case Studies
Figure 9. Cervical Cancer Case Studies
Figure 10. Pancreatic Cancer Case Studies
Figure 11. Non-small Cell Lung Cancer Case Studies
Figure 12. Other Case Studies
Figure 13. Paclitaxel and Its Analogue in Anticarcinoma Drugs Report Years Considered
Figure 14. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Regions: 2020 VS 2026
Figure 16. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Players in 2019
Figure 19. Global Top Paclitaxel and Its Analogue in Anticarcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue in 2019
Figure 21. North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Bristol-Myers Squibb Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 30. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Celgene Corporation Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 32. Hospira Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Hospira Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 34. Biological E. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Biological E. Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 36. Taj Accura Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Taj Accura Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 38. Khandelwal Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Khandelwal Laboratories Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 40. Luye Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Luye Pharma Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 42. Beijing Youcare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Beijing Youcare Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 44. Beijing Union Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Beijing Union Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 46. Haiyao Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Haiyao Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 48. Chuntch Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Chuntch Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 50. Hengrui Medicine Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Hengrui Medicine Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 52. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Sanofi Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 54. Qilu Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Qilu Pharma Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 56. Shenzhen Main Luck Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Shenzhen Main Luck Pharma Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 58. Jiangsu Aosaikang Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Jiangsu Aosaikang Pharma Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 60. CSPC Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. CSPC Pharmaceutical Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 62. Aosaikang Pharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Aosaikang Pharm Revenue Growth Rate in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2015-2020)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed